Purchase Order W81K0026PA004
Award Date 11/15/25
Potential Completion Date 9/30/30
Potential Value $521K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
2330 Stanley Rd, Fort Sam Houston, TX 78234, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Health Agency awarded a $21,834 firm-fixed-price Blanket Purchase Agreement (BPA) call to Sun Pharmaceutical Industries, Inc. for the supply of radiopharmaceuticals for nuclear medicine. The contract, which has no set-aside designation, will run through September 30, 2025. Sun Pharmaceutical, a for-profit manufacturer, has received previous prime contract awards from the Defense Health Agency for nuclear medicine imaging products, radiopharmaceutical delivery services, and...
- This federal contract award to Sun Pharmaceutical Industries, Inc. by the Defense Health Agency is for the provision of nuclear medicine imaging products. The $986,924.50 firm-fixed-price purchase order covers the supply of medical imaging products for myocardial infarct imaging, diagnostic imaging of gallbladder disorders, and breast cancer nodule imaging. The contract has an ultimate completion date of March 11, 2026. This award is associated with Sun Pharmaceutical's existing Federal Supply...
- This is a federal contract award to Sun Pharmaceutical Industries, Inc., a for-profit manufacturer of pharmaceutical and radiopharmaceutical products, by the Defense Health Agency. The contract is for the provision of radiopharmaceuticals, with a ceiling value of $21,839.00 and a firm fixed-price pricing type. The contract has an ultimate completion date of September 30, 2025. Sun Pharmaceutical Industries, Inc. holds a significant Federal Supply Schedule contract with the Defense Health...
- The Defense Health Agency awarded a $246,103.48 firm fixed-price purchase order to Petnet Solutions, Inc. for the supply of various radiopharmaceuticals to support the Department of Radiology, Nuclear Medicine Service at William Beaumont Army Medical Center in Fort Bliss, Texas. The contract, which commenced on October 1, 2025, and concludes on September 30, 2026, was awarded without a set-aside designation, reflecting open competition. Petnet Solutions, a Siemens subsidiary headquartered in...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA), a component of the Department of Defense, to Pharmalucence, Inc., a specialty pharmaceutical manufacturer. The $17,447 contract is for the delivery of molecular imaging products for nuclear medicine, specifically Pharmalucence's SC05 Sulfur Colloid radiopharmaceutical kits. The contract has no set-aside designation, indicating open competition. Pharmalucence, Inc. is a for-profit, Subchapter S Corporation...
- The Defense Health Agency awarded a $73,365 firm fixed price call against its Basic Purchasing Agreement (BPA) for radiopharmaceuticals to Medi-Physics, Inc., a subsidiary of General Electric Company. Under this contract, Medi-Physics will provide radiopharmaceutical products and services to DHA facilities from its performance location in Fort Sam Houston, Texas through September 11, 2023. As the DHA works to ensure service members and their families have access to quality healthcare, this...
- The Defense Health Agency awarded a $427,002.42 firm fixed-price purchase order to RLS (USA) Inc. for radiopharmaceuticals, effective October 1, 2025, with performance completion targeted for September 30, 2029. The contract is to be performed at Fort Cavazos, Texas, and includes no set-aside designation. RLS (USA) Inc., a foreign-owned radiopharmacy company operating 31 facilities across 18 states, specializes in supplying time-sensitive radiopharmaceutical products to federal healthcare...
- <p>The U.S. Defense Health Agency (DHA) awarded a Firm Fixed Price purchase order contract to Michael N. Clemenshaw, LLC, a Service Disabled Veteran Owned Small Business, for NUCLEAR MEDICINE & DX RADIOLOGIST services. The $2,520,631.83 contract has an ultimate completion date of October 31, 2027 and was set aside for small businesses. The place of performance is located at Fort Sam Houston, Texas.</p>
- This is a firm fixed price blanket purchase agreement (BPA) call contract awarded by the Defense Health Agency (DHA) to Pharmalucence, Inc. for the supply of radiopharmaceuticals and related products. The contract has a ceiling value of $75,000.00 and a period of performance through September 30, 2024. Pharmalucence, Inc. is a specialty pharmaceutical company focused on manufacturing and distributing generic radiopharmaceutical products and supplies. The DHA, a component of the Department of...
- This firm fixed-price purchase order for $124,815.00 was awarded by the Defense Health Agency (DHA) to Pharmalucence, Inc., a specialty pharmaceutical company focused on manufacturing and distributing generic radiopharmaceutical products and supplies. The contract is for the delivery of SC05 Sulfur Colloid 5 vials/box to support nuclear medicine diagnostic services for active duty personnel and their families within the Military Health System. Pharmalucence, Inc. has been awarded multiple...